Synthesis and biological evaluation of substituted pyrazoles as blockers of divalent metal transporter 1 (DMT1)

  • Bioorg Med Chem Lett. 2012 Jan 1;22(1):90-5. doi: 10.1016/j.bmcl.2011.11.069.
Jay A Cadieux  1 ,  Zaihui Zhang ,  Maryanne Mattice ,  Alison Brownlie-Cutts ,  Jianmin Fu ,  Laszlo G Ratkay ,  Rainbow Kwan ,  Jay Thompson ,  Joseph Sanghara ,  Jing Zhong ,  Y Paul Goldberg
Affiliations
  • 1. Department of Medicinal Chemistry, Xenon Pharmaceuticals Inc., 3650 Gilmore Way, Burnaby, British Columbia, Canada V5G 4W8. [email protected]
Abstract

Three distinct series of substituted pyrazole blockers of divalent metal transporter 1 (DMT1) were elaborated from the high-throughput screening pyrazolone hit 1. Preliminary hit-to-lead efforts revealed a preference for electron-withdrawing substituents in the 4-amido-5-hydroxypyrazole series 6a-l. In turn, this preference was more pronounced in a series of 4-aryl-5-hydroxypyrazoles 8a-j. The representative analogs 6f and 12f were found to be efficacious in a rodent model of acute iron hyperabsorption. These three series represent promising starting points for lead optimization efforts aimed at the discovery of DMT1 blockers as iron overload therapeutics.

Products